Scholarlink

Introduction <p>This study aimed to evaluate visual outcomes and patient satisfaction following implantation of a non-diffractive extended depth of focus (EDOF) intraocular lens (IOL) in eyes with cataract developing after pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD).</p> Methods <p>Patients who underwent PPV for RRD, with or without macular involvement, and subsequently developed cataract were prospectively enrolled. Cataract surgery was performed with implantation of the Vivity EDOF-IOL (Alcon). Bilateral implantation was performed according to patient preference. Inclusion criteria were attached retina 3–6&#xa0;months after PPV and corrected distant visual acuity of 0.3–0.7&#xa0;logMAR. Primary outcomes were monocular and binocular, corrected and uncorrected distance, intermediate, and near visual acuity (CDVA, UDVA, DCIVA, UIVA, DCNVA, UNVA) at 6&#xa0;months. Secondary outcomes included defocus curve and patient-reported satisfaction.</p> Results <p>Twenty-seven patients (43 eyes) underwent surgery at 6 ± 3&#xa0;months after PPV (16 patients bilateral). Thirteen patients had RRD with macular involvement. In the RRD-affected eyes CDVA improved statistically significantly from 0.35 ± 0.16 to 0.03 ± 0.12 and UDVA from 1.01 ± 0.34 to 0.16 ± 0.19&#xa0;logMAR at 6&#xa0;months. Mean visual acuities at 6&#xa0;months for RRD-affected eyes were DCIVA 0.53 ± 0.21, UIVA 0.44 ± 0.15, DCNVA 0.59 ± 0.23, and UNVA 0.47 ± 0.23&#xa0;logMAR. Binocular UDVA, UIVA, and UNVA for the bilateral cases were − 0.04 ± 0.11, 0.29 ± 0.10, and 0.26 ± 0.13&#xa0;logMAR, respectively. The defocus curve was comparable between macula-on, macula-off, and fellow eyes. Patient satisfaction was favorable with just two patients reporting halos.</p> Conclusion <p>Using the Vivity EDOF-IOL in selected patients with cataract after successful PPV for RRD appears to be a safe and effective option, yielding favorable visual outcomes regardless of macular involvement.</p> Trial Registration Number <p>DRKS00037029.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Extended Depth of Field Intraocular Lens for Cataract After Vitrectomy for Retinal Detachment: A Prospective Trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月25日

查看全文
  • Efstathios Vounotrypidis,
  • Dorian Begaj,
  • Rupert Kamnig,
  • Julie Meyer,
  • Melih Parlak,
  • Christian M. Wertheimer,
  • Armin Wolf

摘要

Introduction

This study aimed to evaluate visual outcomes and patient satisfaction following implantation of a non-diffractive extended depth of focus (EDOF) intraocular lens (IOL) in eyes with cataract developing after pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD).

Methods

Patients who underwent PPV for RRD, with or without macular involvement, and subsequently developed cataract were prospectively enrolled. Cataract surgery was performed with implantation of the Vivity EDOF-IOL (Alcon). Bilateral implantation was performed according to patient preference. Inclusion criteria were attached retina 3–6 months after PPV and corrected distant visual acuity of 0.3–0.7 logMAR. Primary outcomes were monocular and binocular, corrected and uncorrected distance, intermediate, and near visual acuity (CDVA, UDVA, DCIVA, UIVA, DCNVA, UNVA) at 6 months. Secondary outcomes included defocus curve and patient-reported satisfaction.

Results

Twenty-seven patients (43 eyes) underwent surgery at 6 ± 3 months after PPV (16 patients bilateral). Thirteen patients had RRD with macular involvement. In the RRD-affected eyes CDVA improved statistically significantly from 0.35 ± 0.16 to 0.03 ± 0.12 and UDVA from 1.01 ± 0.34 to 0.16 ± 0.19 logMAR at 6 months. Mean visual acuities at 6 months for RRD-affected eyes were DCIVA 0.53 ± 0.21, UIVA 0.44 ± 0.15, DCNVA 0.59 ± 0.23, and UNVA 0.47 ± 0.23 logMAR. Binocular UDVA, UIVA, and UNVA for the bilateral cases were − 0.04 ± 0.11, 0.29 ± 0.10, and 0.26 ± 0.13 logMAR, respectively. The defocus curve was comparable between macula-on, macula-off, and fellow eyes. Patient satisfaction was favorable with just two patients reporting halos.

Conclusion

Using the Vivity EDOF-IOL in selected patients with cataract after successful PPV for RRD appears to be a safe and effective option, yielding favorable visual outcomes regardless of macular involvement.

Trial Registration Number

DRKS00037029.